مجله دانشکده پزشکی اصفهان

مجله دانشکده پزشکی اصفهان

هپاتیت B در مبتلایان به بیماری مرحله‌ی پایانی کلیه، تحت درمان با همودیالیز

نوع مقاله : مقاله مروری

نویسندگان
سید سیف‌اله بلادی موسوی 1
حشمت‌اله شهبازیان 2
محمد فرامرزی 3
سمانه خدادادی 4
حمید نصری 5
1 دانشیار، مرکز تحقیقات نارسایی مزمن کلیه، دانشگاه علوم پزشکی جندی‌شاپور اهواز، اهواز، ایران
2 استاد، مرکز تحقیقات نارسایی مزمن کلیه، دانشگاه علوم پزشکی جندی‌شاپور اهواز، اهواز، ایران
3 دانشجوی پزشکی، مرکز تحقیقات نارسایی مزمن کلیه، دانشگاه علوم پزشکی جندی‌شاپور اهواز، اهواز، ایران
4 انستیتو پژوهشی نیکان، اصفهان، ایران
5 استاد، گروه داخلی، دانشکده‌ی پزشکی، دانشگاه علوم پزشکی اصفهان، اصفهان، ایران
چکیده
با وجود همه‌ی روش‌های پیش‌گیری، ویروس هپاتیت B (HBV یا Hepatitis B virus)، که می‌تواند عامل ایجاد هپاتیت حاد و مزمن، سیروز و سرطان کبد باشد، همچنان در بسیاری از مناطق به صورت اندمیک باقی مانده است و بیش از 350 میلیون نفر در جهان ناقل مزمن این ویروس هستند. بروز عفونت هپاتیت B در بیماران با نارسایی مزمن کلیه در طول چند دهه‌ی گذشته، به دنبال اقداماتی نظیر غربال‌گری خون از نظر Hepatitis B surface antigen (HBsAg) و Anti-Hepatitis B core total antibodies (Anti-HBc)، کاهش نیاز به انتقال خون پس از پیدایش اریتروپویتین واکسیناسیون هپاتیت B و انجام اقدامات کنترل عفونت در واحدهای همودیالیز به طور قابل توجهی کاهش یافته است. به نظر می‌رسد که در اکثر بیماران مبتلا به بیماری مرحله‌ی پایانی کلیه، آزمایش HBsAg برای تشخیص عفونت ویروس هپاتیت B کافی است. با این وجود، با توجه به این که علایم بیوشیمیایی اغلب نمی‌تواند به طور قابل اعتمادی وضعیت بافت‌شناسی کبد را نشان دهد، بیوپسی کبدی بهترین روش برای ارزیابی فعالیت هپاتیت B و درجه‌ی سیروز می‌باشد. بیوپسی کبد، اغلب هنگامی توصیه می‌شود که درمان آنتی‌ویروس و قبل از آن، انجام پیوند کلیه برای ارزیابی شدت بیماری کبدی ناشی از HBV مد نظر باشد. با توجه به عوارض جانبی اینترفرون آلفا در بیماران تحت دیالیز، آنالوگ‌های نوکلئوزیدی، انتخاب‌های بهتری در درمان هپاتیت B این بیماران می‌باشند. در پایان، باید اشاره شود که انتکاویر خوراکی، اولین خط درمان توصیه شده برای هپاتیت B در این بیماران می‌باشد.
کلیدواژه‌ها
هپاتیت B
نارسایی مزمن کلیه
همودیالیز

عنوان مقاله English

Hepatitis B in Patients with End-Stage Renal Disease Undergoing Maintenance Hemodialysis

نویسندگان English

Seyed Seifollah Beladi-Mousavi 1
Heshmatollah Shahbazian 2
Mohammad Faramarzi 3
Samaneh khodadadi 4
Hamid Nasri 5
1 Associate Professor, Chronic Renal Failure Research Center, Jundishapour University of Medical Sciences, Ahwaz, Iran
2 Professor, Chronic Renal Failure Research Center, Jundishapour University of Medical Sciences, Ahwaz, Iran
3 Student of Medicine, Chronic Renal Failure Research Center, Jundishapour University of Medical Sciences, Ahvaz, Iran
4 Nickan Research Institute, Isfahan, Iran
5 Professor, Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
چکیده English

Despite all prevention methods, hepatitis B virus (HBV), which can cause acute and chronic hepatitis, cirrhosis and liver cancer, still has remained endemic in many areas and more than 350 million people are chronic carriers of this virus in the world. The incidence of hepatitis B infection has significantly decreased among the patients with end stage renal disease during the past few decades due to factors such as blood screening for HBsAg and anti-HBc, reducing the need for blood transfusion after the advent of erythropoietin, hepatitis B vaccination and the implementation of infection control measures in hemodialysis units. It seems that HBsAg test is sufficient for the diagnosis of HBV infection in most end stage renal disease (ESRD) patients. However since the biochemical tests often cannot be reliable to indicate the status of liver pathology, the liver biopsy is the best method to ascertain the activity of hepatitis and the degree of cirrhosis. It is often recommended when antiviral treatment is being considered and before kidney transplantation for assesses the activity of HBV-related liver disease. According to the side effects of interferon-alfa among dialysis patients, nucleoside analogs are better choices for the treatment of hepatitis B among these patients. Finally it should be noted that Entecavir is the recommended first-line oral medication for hepatitis B among these patients.

کلیدواژه‌ها English

Hepatitis B
Chronic renal failure
Hemodialysis
  1. Beladi-Mousavi SS, Faramarzi M. Calcimimetic agents in the management of secondary hyperparathyroidism among patients with end-stage renal disease; a review article. J Parathyr Dis 2015; 3(1): 12-9.
  2. Harnett JD, Parfrey PS, Kennedy M, Zeldis JB, Steinman TI, Guttmann RD. The long-term outcome of hepatitis B infection in hemodialysis patients. Am J Kidney Dis 1988; 11(3): 210-3.
  3. Chow KM, Szeto CC, Wu AK, Leung CB, Kwan BC, Li PK. Continuous ambulatory peritoneal dialysis in patients with hepatitis B liver disease. Perit Dial Int 2006; 26(2): 213-7.
  4. Tamadon MR, Beladi-Mousavi SS. Erythropoietin; a review on current knowledge and new concepts. J Renal Inj Prev 2013; 2(4): 119-21.
  5. Rostaing L, Izopet J, Kamar N. Hepatitis C virus infection in nephrology patients. J Nephropathol 2013; 2(4): 217-33.
  6. Nasri H, Dehghan Shahreza F. Defensins usage as novel therapeutic and diagnostic approach. Immunopathol Persa 2015; 1(1): e05.
  7. Nasri H. Antioxidants; from laboratory investigations to clinical studies. Ann Res Antioxid 2016; 1(2): e19.
  8. Mardani S, Tamadon MR, Shahbazian H, Beladi Mousavi SS, Ardalan MR, Nasri H. Aggressive jaw brown tumor in a 28-year-old man with long-lasted chronic kidney disease. J Parathyr Dis 2015; 3(1): 8-9.
  9. Nasri H, Abedi-Gheshlaghi Z, Rafieian-Kopaei M. Curcumin and kidney protection; current findings and new concepts. Acta Persica Pathophysiol 2016; 1(1): e01.
  10. Hernandez GT, Nasri H. World Kidney Day 2014: increasing awareness of chronic kidney disease and aging. J Renal Inj Prev 2014; 3(1): 3-4.
  11. Mardani M, Rezapour P, Baba H, Balavar S, Naghdi N. The nutritional status of hemodialysis patients admitted to Khoramabad's Shohadie Ashaier hospital, Korramabad, Iran. J Prev Epidemiol 2016; 1(1): e09.
  12. Baradaran A, Behradmanesh S, Nasri H. Association of body mass index and serum vitamin D level in healthy Iranian adolescents. Endokrynol Pol 2012; 63(1): 29-33.
  13. Jafari T. Nutritional assessment in patients on hemodialysis. J Prev Epidemiol 2016; 1(1): e08.
  14. Baradaran A. Concepts towards endothelial dysfunction in diabetes mellitus. Angiologica Persica Acta 2016;1:e02.
  15. Dehghan Shahreza F. From oxidative stress to endothelial cell dysfunction. J Prev Epidemiol 2016; 1(1): e04.
  16. Momeni A. Cardiovascular complications of renal failure in hemodialysis patients. Ann Res Dial 2016; 1(1): e05.
  17. Ahmed SMA, Nazar CMJ, Khurshid T, Abdul Aziz J. A literature review of the effectiveness of primary prevention measures to reduce transmission of hepatitis C infection in injecting drug users. Immunopathol Persa 2016; 2(1): e05.
  18. Rafieian-Kopaei M, Nasri H. Vitamin D therapy in diabetic kidney disease. J Nephropharmacol 2014; 3(1): 3-4.
  19. Dehghan Shahreza F. Mechanistic impact of renal tubular cell protection by antioxidants. Ann Res Antioxid 2016; 1(1): e11.
  20. Amiri M, Hosseini SM. Diabetes mellitus type 1; is it a global challenge? Acta Epidemioendocrinol 2016; 1(1): e02.
  21. Asadi-Samani M, Bahmani M. Trends on the treatment of atherosclerosis; new improvements. Angiologica Persica Acta 2016; 1(1): e01.
  22. Baradaran A. Lipoprotein(a), type 2 diabetes and nephropathy; the mystery continues. J Nephropathol 2012; 1(3): 126-9.
  23. Ezeonwu BU, Nwafor I, Nnodim I, Ayodeji A, Ajaegbu O, Maduemem E,et al. Risk factors for chronic kidney diseasein children attending pediatric outpatient clinic in federal medical center Asaba. J Prev Epidemiol 2016; 1(2): e10.
  24. Nasri H, Baradaran A. Correlation of serum magnesium with dyslipidemia in maintenance hemodialysis patients. Acta Medica (Hradec Kralove) 2004; 47(4): 263-5.
  25. Hajibabaei K. Antioxidant properties of vitamin E. Ann Res Antioxid 2016; 1(2): e22.
  26. Nazar CMJ, Ahmed A, Akhtar MH, Kareem N. The awareness levels, attitude and perception of people about diabetes. J Renal Endocrinol 2016; 2(1): e01.
  27. Friedlaender MM, Kaspa RT, Rubinger D, Silver J, Popovtzer MM. Renal transplantation is not contraindicated in asymptomatic carriers of hepatitis B surface antigen. Am J Kidney Dis 1989; 14(3): 204-10.
  28. Pirson Y, Alexandre GP, Ypersele C. Long-term effect of hbs antigenemia on patient survival after renal transplantation. N Engl J Med 1977; 296(4): 194-6.
  29. Weir MR, Kirkman RL, Strom TB, Tilney NL. Liver disease in recipients of long-functioning renal allografts. Kidney Int 1985; 28(5): 839-44.
  30. Beladi Mousavi SS, Sametzadeh M, Hayati F, Fatemi SM. Evaluation of acquired cystic kidney disease in patients on hemodialysis with ultrasonography. Iran J Kidney Dis 2010; 4(3): 223-6.
  31. Amiri M. Type 2 diabetes mellitus; an international challenge. Ann Res Dial 2016; 1(1): e04.
  32. Feily A, Dormanesh B, Ghorbani AR, Moosavi Z, Kouchak M, Cheraghian B, et al. Efficacy of topical cromolyn sodium 4% on pruritus in uremic nephrogenic patients: a randomized double-blind study in 60 patients. Int J Clin Pharmacol Ther 2012; 50(7): 510-3.
  33. Beladi-Mousavi SS, Beladi-Mousavi M, Hayati F, Talebzadeh M. Effect of intranasal DDAVP in prevention of hypotension during hemodialysis. Nefrologia 2012; 32(1): 89-93.
  34. Beladi-Mousavi SS, Faramarzi M. Calcimimetic agents in the management of secondary hyperparathyroidism among patients with end-stage renal disease; a review article. J Parathyr Dis 2015; 3(1): 12-9.
  35. Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 2005; 18(1): 52-61.
  36. Oguchi H, Miyasaka M, Tokunaga S, Hora K, Ichikawa S, Ochi T, et al. Hepatitis virus infection (HBV and HCV) in eleven Japanese hemodialysis units. Clin Nephrol 1992; 38(1): 36-43.
  37. Hajian S. Positive effect of antioxidants on immune system. Immunopathol Persa 2015; 1(1): e02.
  38. Johnson DW, Dent H, Yao Q, Tranaeus A, Huang CC, Han DS, et al. Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries: analysis of registry data. Nephrol Dial Transplant 2009; 24(5): 1598-603.
  39. Fabrizi, F, Martin, P. Management of hepatitis B and C virus infection before and after renal transplantation. Curr Opin Organ Transplant 2006; 11(6): 583-8.
  40. Mioli VA, Balestra E, Bibiano L, Carletti P, Della BS, Fanciulli E, et al. Epidemiology of viral hepatitis in dialysis centers: a national survey. Nephron 1992; 61(3): 278-83.
  41. Teles SA, Martins RM, Vanderborght B, Stuyver L, Gaspar AM, Yoshida CF. Hepatitis B virus: genotypes and subtypes in Brazilian hemodialysis patients. Artif Organs 1999; 23(12): 1074-8.
  42. Beladi-Mousavi SS, Hajiani E, Salehi-Behbehani SM. Hepatitis B Infection in ESRD Patients in Khuzestan Province, Iran. Iran J Virol 2010; 4(2): 45-8.
  43. Tokars JI, Alter MJ, Miller E, Moyer LA, Favero MS. National surveillance of dialysis associated diseases in the United States--1994. ASAIO J 1997; 43(1): 108-19.
  44. Burdick RA, Bragg-Gresham JL, Woods JD, Hedderwick SA, Kurokawa K, Combe C, et al. Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int 2003; 63(6): 2222-9.
  45. Centers for Disease Control and Prevention. Outbreaks of hepatitis B virus infection among hemodialysis patients-- California, Nebraska, and Texas, 1994. MMWR Morb Mortal Wkly Rep 1996; 45(14): 285-9.
  46. Andrew R, Hariharan S, Saha V, John JT, Kirubakaran MG, Shastry JC. Biochemical evaluation of ultrafiltrate in dialysis-dependent HBsAG-positive patients. Nephron 1988; 49(1): 88.
  47. Kroes AC, van Bommel EF, Niesters HG, Weimar W. Hepatitis B viral DNA detectable in dialysate. Nephron 1994; 67(3): 369.
  48. Cendoroglo NM, Draibe SA, Silva AE, Ferraz ML, Granato C, Pereira CA, et al. Incidence of and risk factors for hepatitis B virus and hepatitis C virus infection among haemodialysis and CAPD patients: evidence for environmental transmission. Nephrol Dial Transplant 1995; 10(2): 240-6.
  49. Chan TM, Wu PC, Li FK, Lai CL, Cheng IK, Lai KN. Treatment of fibrosing cholestatic hepatitis with lamivudine. Gastroenterology 1998; 115(1): 177-81.
  50. Hui CK, Sun J, Au WY, Lie AK, Yueng YH, Zhang HY, et al. Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. J Hepatol 2005; 42(6): 813-9.
  51. Minuk GY, Sun DF, Greenberg R, Zhang M, Hawkins K, Uhanova J, et al. Occult hepatitis B virus infection in a North American adult hemodialysis patient population. Hepatology 2004; 40(5): 1072-7.
  52. Favero MS, Bond WW, Petersen NJ, Berquist KR, Maynard JE. Detection methods for study of the stability of hepatitis B antigen on surfaces. J Infect Dis 1974; 129(2): 210-2.
  53. Hamzic-Mehmedbasic A, Rasic S, Balavac M, Rebic D, Delic-Sarac M, Durak-Nalbantic A. Prognostic indicators of adverse renal outcome and death in acute kidney injury hospital survivors. J Renal Inj Prev 2016; 5(2): 61-68.
  54. Kellerman S, Alter MJ. Preventing hepatitis B and hepatitis C virus infections in end-stage renal disease patients: back to basics. Hepatology 1999; 29(1): 291-3.
  55. Bruce MG, Bruden D, Hurlburt D, Zanis C, Thompson G, Rea L, et al. Antibody levels and protection after hepatitis B vaccine: results of a 30-year follow-up study and response to a booster dose. J Infect Dis 2016; 214(1): 16-22.
  56. Beladi-Mousavi SS, Hajibabaei K, Hamledari A, Tamadon MR, Ardalan MR. Introduction to chemical construction of immunotoxins and their applications in the treatment of diseases. Immunopathol Persa. 2016;2(1):e02.
  57. Mousavi SS, Soleimani A, Mousavi MB. Epidemiology of end-stage renal disease in Iran: a review article. Saudi J Kidney Dis Transpl 2014; 25(3): 697-702.
  58. Tokars JI, Finelli L, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2001. Semin Dial 2004; 17(4): 310-9.
  59. Miller ER, Alter MJ, Tokars JI. Protective effect of hepatitis B vaccine in chronic hemodialysis patients. Am J Kidney Dis 1999; 33(2): 356-60.
  60. Kafeshani M. Ginger, micro-inflammation and kidney disease. J Renal Endocrinol 2015; 1: e04.
  61. Momeni A. The best method of hepatitis B vaccination in hemodialysis patients? J Renal Inj Prev 2013; 2(4): 125-6.
  62. Degott C, Degos F, Jungers P, Naret C, Courouce AM, Potet F, et al. Relationship between liver histopathological changes and HBsAg in 111 patients treated by long-term hemodialysis. Liver 1983; 3(6): 377-84.
  63. Coughlin GP, Van Deth AG, Disney AP, Hay J, Wangel AG. Liver disease and the e antigen in HBsAg carriers with chronic renal failure. Gut 1980; 21(2): 118-22.
  64. Josselson J, Kyser BA, Weir MR, Sadler JH. Hepatitis B surface antigenemia in a chronic hemodialysis program: lack of influence on morbidity and mortality. Am J Kidney Dis 1987; 9(6): 456-61.
  65. Beladi-Mousavi SS, Alemzadeh-Ansari MJ, Alemzadeh-Ansari MH, Beladi-Mousavi M. Long-term survival of patients with end-stage renal disease on maintenance hemodialysis: a multicenter study in Iran. Iran J Kidney Dis 2012; 6(6): 452-6.
  66. Litjens NH, Huisman M, van den Dorpel M, Betjes MG. Impaired immune responses and antigen-specific memory CD4+ T cells in hemodialysis patients. J Am Soc Nephrol 2008; 19(8): 1483-90.
  67. Khodadadi S. Role of herbal medicine in boosting immune system. Immunopathol Persa 2015; 1(1): e01.
  68. Marzano A, Angelucci E, Andreone P, Brunetto M, Bruno R, Burra P, et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 2007; 39(5): 397-408.
  69. Papatheodoridis GV, Manolakopoulos S, Dusheiko G, Archimandritis AJ. Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis 2008; 8(3): 167-78.
  70. European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57(1): 167-85.
  71. Beladi Mousavi SS, Hajiani E, Hayati F, Hashemi SJ, Shayesteh A, Salehi Behbehani SM, et al. Epidemiology of hepatitis C virus infection in ESRD patients in Khuzestan province, Iran. Shiraz E Med J 2012; 13(3): 135-40.
  72. Regev A, Schiff ER. Drug therapy for hepatitis B. Adv Intern Med 2001; 46: 107-35.
  73. Jafri SM, Lok AS. Antiviral therapy for chronic hepatitis B. Clin Liver Dis 2010; 14(3): 425-38.
  74. Duarte-Rojo A, Heathcote EJ. Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B. Therap Adv Gastroenterol 2010; 3(2): 107-19.
  75. Girndt M, Kohler H. Hepatitis B virus infection in hemodialysis patients. Semin Nephrol 2002; 22(4): 340-50.
  76. Rafieian-Kopaei M, Baradaran A. On the occasion of world diabetes day 2105; act today to change tomorrow. J Renal Endocrinol 2015; 1: e02.
  77. Schmilovitz-Weiss H, Melzer E, Tur-Kaspa R, Ben-Ari Z. Excellent outcome of Lamivudine treatment in patients with chronic renal failure and hepatitis B virus infection. J Clin Gastroenterol 2003; 37(1): 64-7.
  78. Kletzmayr J, Watschinger B, Muller C, Demetriou D, Puchhammer-Stockl E, Ferenci P, et al. Twelve months of lamivudine treatment for chronic hepatitis B virus infection in renal transplant recipients. Transplantation 2000; 70(9): 1404-7.
  79. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119(1): 172-80.
  80. Schiff ER, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003; 38(6): 1419-27.
  81. Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32(1): 129-34.
  82. de Man RA, Wolters LM, Nevens F, Chua D, Sherman M, Lai CL, et al. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology 2001; 34(3): 578-82.
  83. Chang TT, Gish RG, Hadziyannis SJ, Cianciara J, Rizzetto M, Schiff ER, et al. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005; 129(4): 1198-209.
  84. Beladi-Mousavi SS, Hajibabaei K, Tamadon MR, Rafieian-Kopaei M. Relationship between free radicals and risk of kidney diseases; the role of antioxidants and their reaction mechanisms. Ann Res Antioxid 2016; 1(1): e02.
  85. Nasri H. Antioxidant therapy for hemodialysis patients. Ann Res Antioxid 2016; 1(1): e01.
  86. Mirhoseini M, Baradaran A, Rafieian-Kopaei M. Medicinal plants, diabetes mellitus and urgent needs. J Herbmed Pharmacol 2013; 2(2): 53-4.
مجله دانشکده پزشکی اصفهان
دوره 34، شماره 380 - شماره پیاپی 380
خرداد و تیر 1395
صفحه 450-459

  • تاریخ دریافت 16 اردیبهشت 1394
  • تاریخ پذیرش 17 فروردین 1401